Data gathered: May 29
AI Stock Analysis - Sarepta Therapeutics (SRPT)
Analysis generated January 18, 2025. Powered by Chat GPT.
Sarepta Therapeutics, Inc. is a biopharmaceutical company specializing in the development of innovative genetic medicine to treat rare diseases. The company focuses particularly on rare neuromuscular diseases. Sarepta Therapeutics is a leader in gene therapy and has a robust pipeline of potential treatments for Duchenne Muscular Dystrophy (DMD) and other similar conditions.
Stock Alerts - Sarepta Therapeutics (SRPT)
 |
Sarepta Therapeutics | May 27 Employee Rating is down by 7% over the last month. |
|
Sarepta Therapeutics | May 27 Business Outlook among employees is down by 8.2% over the last month. |
|
Sarepta Therapeutics | May 21 Price is up by 8.8% in the last 24h. |
|
Sarepta Therapeutics | May 12 Price is up by 7.1% in the last 24h. |
Download our app to get future alerts delivered in real-time.
Alternative Data for Sarepta Therapeutics
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 64 | Sign up | Sign up | Sign up |
| Sentiment | 91 | Sign up | Sign up | Sign up |
| Webpage traffic | 34,000 | Sign up | Sign up | Sign up |
| Employee Rating | 80 | Sign up | Sign up | Sign up |
| Google Trends | 31 | Sign up | Sign up | Sign up |
| Patents | 121 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Facebook Engagement | 1,229 | Sign up | Sign up | Sign up |
| Facebook Followers | 9,291 | Sign up | Sign up | Sign up |
| Instagram Followers | 5,509 | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 121 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 20,535 | Sign up | Sign up | Sign up |
| Twitter Followers | 5,878 | Sign up | Sign up | Sign up |
| Twitter Mentions | 54 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Lobbying Cost | $107,000 | Sign up | Sign up | Sign up |
| Business Outlook | 67 | Sign up | Sign up | Sign up |
| Linkedin Employees | 1,544 | Sign up | Sign up | Sign up |
About Sarepta Therapeutics
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases.
| Price | $37.23 |
| Target Price | Sign up |
| Volume | 3,270,000 |
| Market Cap | $3.77B |
| Year Range | $35.27 - $137.94 |
| Dividend Yield | 0% |
| PE Ratio | 27.21 |
| Analyst Rating | 95% buy |
| Industry | Biotechnology |
In the news
 |
Was Jim Cramer Right About Sarepta Therapeutics Inc. (SRPT)?May 27 - Biztoc.com |
 |
Sarepta Therapeutics (NASDAQ:SRPT) Receives Neutral Rating from HC WainwrightMay 24 - ETF Daily News |
|
Focus Partners Wealth Boosts Stock Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)May 23 - ETF Daily News |
SRPT Investigation Reminder: Kessler Topaz Meltzer & Check, LLP Encourages Sarepta Therapeutics, Inc. (NASDAQMay 22 - Finnhub |
|
|
Cetera Investment Advisers Buys 463 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)May 22 - ETF Daily News |
|
Sarepta Therapeutics (NASDAQ:SRPT) Given New $84.00 Price Target at JPMorgan Chase & Co.May 21 - ETF Daily News |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q1 '25 | 745M | 138M | 607M | -448M | 0 | 0.000 |
| Q4 '24 | 658M | 132M | 526M | 159M | 191M | 1.900 |
| Q3 '24 | 467M | 92M | 375M | 34M | 49M | 0.340 |
| Q2 '24 | 363M | 53M | 310M | 6.5M | 12M | 0.070 |
| Q1 '24 | 413M | 51M | 363M | 36M | 58M | 0.370 |
Insider Transactions View All
| Nicaise Claude filed to sell 27,812 shares at $99.6. March 13 '25 |
| Wigzell Hans Lennart Rudolf filed to sell 22,840 shares at $124.8. December 16 '24 |
| Boor Kathryn Jean filed to sell 5,880 shares at $125.6. December 6 '24 |
| Estepan Ian Michael filed to sell 33,946 shares at $137.4. September 3 '24 |
| Chambers Michael Andrew filed to buy 284,034 shares at $134.7. August 20 '24 |
Similar companies
Congress Trading View All
| Politician | Filing Date | Type | Size |
|---|---|---|---|
| Joshua Gottheimer Democrat |
Aug 21, 23 | Buy | $1K - $15K |
| Joshua Gottheimer Democrat |
Jul 11, 23 | Sell | $1K - $15K |
Read more about Sarepta Therapeutics (SRPT) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, facebook engagement, facebook followers, instagram followers, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, news mentions, customer reviews, lobbying cost, business outlook & linkedin employees.
What is the Market Cap of Sarepta Therapeutics?
The Market Cap of Sarepta Therapeutics is $3.77B.
What is Sarepta Therapeutics' PE Ratio?
As of today, Sarepta Therapeutics' PE (Price to Earnings) ratio is 27.21.
What is the current stock price of Sarepta Therapeutics?
Currently, the price of one share of Sarepta Therapeutics stock is $37.23.
How can I analyze the SRPT stock price chart for investment decisions?
The SRPT stock price chart above provides a comprehensive visual representation of Sarepta Therapeutics' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Sarepta Therapeutics shares. Our platform offers an up-to-date SRPT stock price chart, along with technical data analysis and alternative data insights.
Does SRPT offer dividends to its shareholders?
As of our latest update, Sarepta Therapeutics (SRPT) does not offer dividends to its shareholders. Investors interested in Sarepta Therapeutics should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Sarepta Therapeutics?
Some of the similar stocks of Sarepta Therapeutics are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.